All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What is the gold standard for imaging and how can this be implemented globally?
Featured:
Elena ZamagniDuring COMy 2020, Elena Zamagni, University of Bologna, Bologna, IT, spoke to the Multiple Myeloma (MM) Hub. We asked: What is the gold standard for imaging in MM and how can this be implemented globally?
Elena Zamagni outlined the range of imaging techniques currently employed to stage, diagnose, and guide the treatment of MM. Such technologies are used differentially throughout disease progression, from smoldering MM to overt disease. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) was highlighted as the gold standard in MM, but alternative techniques, such as magnetic resonance imaging (MRI), were also discussed.
What is the gold standard for imaging and how can this be implemented globally?
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?